LY3002813 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease
Trial Timeline
Dec 22, 2015 → Aug 28, 2019
NCT ID
NCT02624778About LY3002813 + Placebo
LY3002813 + Placebo is a phase 1 stage product being developed by Eli Lilly for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02624778. Target conditions include Alzheimer Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02624778 | Phase 1 | Completed |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 + Placebo | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| donanemab | Eli Lilly | Phase 2 | 52 |
| ATH-1017 | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 25 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 25 |